{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:17:51Z","timestamp":1787890671796,"version":"build-2784847793"},"reference-count":203,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the joint project on innovation development of the Shandong Provincial Natural Science Fund","award":["ZR2022LSW024"],"award-info":[{"award-number":["ZR2022LSW024"]}]},{"name":"the Clinical Medicine +X Project of Qingdao University","award":["2020018"],"award-info":[{"award-number":["2020018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05365-7","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:55:17Z","timestamp":1781895317000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antitumor effect of dipyridamole mediated by inhibiting the interaction between platelets and tumor cells"],"prefix":"10.1007","volume":"17","author":[{"given":"Jie","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongcui","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"4","key":"5365_CR1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1161\/STROKEAHA.107.496281","volume":"39","author":"P Verro","year":"2008","unstructured":"Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke. 2008;39(4):1358\u201363.","journal-title":"Stroke"},{"issue":"11","key":"5365_CR2","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/jnnp.2008.143875","volume":"79","author":"PH Halkes","year":"2008","unstructured":"Halkes PH, Gray LJ, Bath PM, Diener HC, Guiraud-Chaumeil B, Yatsu FM, et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry. 2008;79(11):1218\u201323.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"5365_CR3","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.bcp.2013.08.063","volume":"86","author":"C Wang","year":"2013","unstructured":"Wang C, Lin W, Playa H, Sun S, Cameron K, Buolamwini JK. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem Pharmacol. 2013;86(11):1531\u201340.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"5365_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1055\/s-0038-1661437","volume":"55","author":"P Gresele","year":"1986","unstructured":"Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost. 1986;55(1):12\u20138.","journal-title":"Thromb Haemost"},{"issue":"4","key":"5365_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1152\/physrev.1995.75.4.725","volume":"75","author":"JA Beavo","year":"1995","unstructured":"Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75(4):725\u201348.","journal-title":"Physiol Rev"},{"issue":"4","key":"5365_CR6","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","volume":"72","author":"P Gresele","year":"2011","unstructured":"Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol. 2011;72(4):634\u201346.","journal-title":"Br J Clin Pharmacol"},{"key":"5365_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0049-3848(83)90356-0","volume":"4","author":"LA Harker","year":"1983","unstructured":"Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res Suppl. 1983;4:39\u201346.","journal-title":"Thromb Res Suppl"},{"issue":"1-2","key":"5365_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0167-4889(01)00086-6","volume":"1539","author":"D Giordano","year":"2001","unstructured":"Giordano D, De Stefano ME, Citro G, Modica A, Giorgi M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta. 2001;1539(1\u20132):16\u201327.","journal-title":"Biochim Biophys Acta"},{"key":"5365_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0079-6468(02)41007-7","volume":"41","author":"H Haning","year":"2003","unstructured":"Haning H, Niew\u00f6hner U, Bischoff E. Phosphodiesterase type 5 (PDE5) inhibitors. Prog Med Chem. 2003;41:249\u2013306.","journal-title":"Prog Med Chem"},{"issue":"2","key":"5365_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0022-3565(25)11019-7","volume":"243","author":"S Seiler","year":"1987","unstructured":"Seiler S, Arnold AJ, Grove RI, Fifer CA, Keely SL Jr., Stanton HC. Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes. J Pharmacol Exp Ther. 1987;243(2):767\u201374.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"5365_CR11","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1111\/j.1538-7836.2010.04019.x","volume":"8","author":"K Lee","year":"2010","unstructured":"Lee K, Kim JY, Yoo BS, Yoon J, Hong MK, Ahn MS, et al. Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders. J Thromb Haemost. 2010;8(11):2577\u20139.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"5365_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123\u201334.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"5365_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/2159-8290.CD-12-0329","volume":"2","author":"M Labelle","year":"2012","unstructured":"Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2012;2(12):1091\u20139.","journal-title":"Cancer Discov"},{"issue":"1","key":"5365_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1055\/s-2002-20564","volume":"28","author":"NM Varki","year":"2002","unstructured":"Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost. 2002;28(1):53\u201366.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"5365_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12967-024-05126-6","volume":"22","author":"J Xue","year":"2024","unstructured":"Xue J, Deng J, Qin H, Yan S, Zhao Z, Qin L, et al. The interaction of platelet-related factors with tumor cells promotes tumor metastasis. J Transl Med. 2024;22(1):371.","journal-title":"J Transl Med"},{"issue":"1","key":"5365_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0669-2","volume":"11","author":"M Schlesinger","year":"2018","unstructured":"Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11(1):125.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"5365_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1349-7006.2009.01419.x","volume":"101","author":"M Iwatsuki","year":"2010","unstructured":"Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010;101(2):293\u20139.","journal-title":"Cancer Sci"},{"issue":"4","key":"5365_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc2620","volume":"9","author":"K Polyak","year":"2009","unstructured":"Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265\u201373.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"5365_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.devcel.2019.04.010","volume":"49","author":"W Lu","year":"2019","unstructured":"Lu W, Kang Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 2019;49(3):361\u201374.","journal-title":"Dev Cell"},{"issue":"16","key":"5365_CR20","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood-2017-05-743187","volume":"131","author":"XR Xu","year":"2018","unstructured":"Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood. 2018;131(16):1777\u201389.","journal-title":"Blood"},{"issue":"1","key":"5365_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12943-021-01347-1","volume":"20","author":"MP Ward","year":"2021","unstructured":"Ward MP, L EK, L AN, Mohamed BM, Kelly T, Bates M, et al. Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell? Mol Cancer. 2021;20(1):59.","journal-title":"Mol Cancer"},{"issue":"5","key":"5365_CR22","volume":"1877","author":"K Morris","year":"2022","unstructured":"Morris K, Schnoor B, Papa AL. Platelet cancer cell interplay as a new therapeutic target. Biochimica et Biophysica Acta (BBA). 2022;1877(5):188770.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"30","key":"5365_CR23","doi-asserted-by":"publisher","first-page":"E3053","DOI":"10.1073\/pnas.1411082111","volume":"111","author":"M Labelle","year":"2014","unstructured":"Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci USA. 2014;111(30):E3053\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"5365_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10555-014-9498-0","volume":"33","author":"DG Menter","year":"2014","unstructured":"Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014;33(1):231\u201369.","journal-title":"Cancer Metastasis Rev"},{"issue":"12","key":"5365_CR25","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1111\/jth.15035","volume":"18","author":"ME Quach","year":"2020","unstructured":"Quach ME, Li R. Structure-function of platelet glycoprotein Ib-IX. J Thromb Haemost. 2020;18(12):3131\u201341.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"5365_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood-2004-06-2272","volume":"105","author":"JS Palumbo","year":"2005","unstructured":"Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1):178\u201385.","journal-title":"Blood"},{"issue":"5","key":"5365_CR27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.7326\/0003-4819-95-5-636","volume":"95","author":"S Karpatkin","year":"1981","unstructured":"Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med. 1981;95(5):636\u201341.","journal-title":"Ann Intern Med"},{"issue":"2","key":"5365_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1538-7836.2010.04131.x","volume":"9","author":"NM Bambace","year":"2011","unstructured":"Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2):237\u201349.","journal-title":"J Thromb Haemost"},{"issue":"50","key":"5365_CR29","doi-asserted-by":"publisher","first-page":"7443","DOI":"10.1038\/sj.onc.1209091","volume":"24","author":"L Larue","year":"2005","unstructured":"Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3\u2019 kinase\/AKT pathways. Oncogene. 2005;24(50):7443\u201354.","journal-title":"Oncogene"},{"issue":"1","key":"5365_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13046-019-1046-x","volume":"38","author":"J Li","year":"2019","unstructured":"Li J, Yang R, Dong Y, Chen M, Wang Y, Wang G. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the \u03b2-catenin\/TCF4 pathway through SPRY2. J Exp Clin Cancer Res. 2019;38(1):38.","journal-title":"J Exp Clin Cancer Res"},{"key":"5365_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ijbiomac.2019.01.144","volume":"128","author":"X Hou","year":"2019","unstructured":"Hou X, Yang L, Jiang X, Liu Z, Li X, Xie S, et al. Role of microRNA-141-3p in the progression and metastasis of hepatocellular carcinoma cell. Int J Biol Macromol. 2019;128:331\u20139.","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"5365_CR32","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871\u201390.","journal-title":"Cell"},{"issue":"1","key":"5365_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000147748","volume":"154","author":"ED Hay","year":"1995","unstructured":"Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel). 1995;154(1):8\u201320.","journal-title":"Acta Anat (Basel)"},{"issue":"6159","key":"5365_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/science.1234850","volume":"342","author":"MA Nieto","year":"2013","unstructured":"Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science. 2013;342(6159):1234850.","journal-title":"Science"},{"key":"5365_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-pathol-020117-043854","volume":"13","author":"V Mittal","year":"2018","unstructured":"Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 2018;13:395\u2013412.","journal-title":"Annu Rev Pathol"},{"issue":"10","key":"5365_CR36","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.tcb.2020.07.003","volume":"30","author":"B Bakir","year":"2020","unstructured":"Bakir B, Chiarella AM, Pitarresi JR, Rustgi AK. EMT, MET, plasticity, and tumor metastasis. Trends Cell Biol. 2020;30(10):764\u201376.","journal-title":"Trends Cell Biol"},{"issue":"1","key":"5365_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166(1):21\u201345.","journal-title":"Cell"},{"issue":"6","key":"5365_CR38","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc3265","volume":"12","author":"T Brabletz","year":"2012","unstructured":"Brabletz T. To differentiate or not\u2013routes towards metastasis. Nat Rev Cancer. 2012;12(6):425\u201336.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"5365_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc3447","volume":"13","author":"B De Craene","year":"2013","unstructured":"De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97\u2013110.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"5365_CR40","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/1878-0261.12096","volume":"11","author":"TT Liao","year":"2017","unstructured":"Liao TT, Yang MH. Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness. Mol Oncol. 2017;11(7):792\u2013804.","journal-title":"Mol Oncol"},{"issue":"6","key":"5365_CR41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2131","volume":"7","author":"H Peinado","year":"2007","unstructured":"Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7(6):415\u201328.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"5365_CR42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"5365_CR43","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1073\/pnas.1918167117","volume":"117","author":"TY Na","year":"2020","unstructured":"Na TY, Schecterson L, Mendonsa AM, Gumbiner BM. The functional activity of E-cadherin controls tumor cell metastasis at multiple steps. Proc Natl Acad Sci USA. 2020;117(11):5931\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"5365_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21(6):341\u201352.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"5365_CR45","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/bjs.8980","volume":"100","author":"S Saadatmand","year":"2013","unstructured":"Saadatmand S, de Kruijf EM, Sajet A, Dekker-Ensink NG, van Nes JG, Putter H, et al. Expression of cell adhesion molecules and prognosis in breast cancer. Br J Surg. 2013;100(2):252\u201360.","journal-title":"Br J Surg"},{"issue":"4","key":"5365_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062171","volume":"8","author":"L Hui","year":"2013","unstructured":"Hui L, Zhang S, Dong X, Tian D, Cui Z, Qiu X. Prognostic significance of twist and N-cadherin expression in NSCLC. PLoS ONE. 2013;8(4):e62171.","journal-title":"PLoS ONE"},{"issue":"7 Pt 1","key":"5365_CR47","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/j.1440-1746.2007.05182.x","volume":"23","author":"DD Seo","year":"2008","unstructured":"Seo DD, Lee HC, Kim HJ, Min HJ, Kim KM, Lim YS, et al. Neural cadherin overexpression is a predictive marker for early postoperative recurrence in hepatocellular carcinoma patients. J Gastroenterol Hepatol. 2008;23(7 Pt 1):1112\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"5365_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109320","volume":"118","author":"ZQ Cao","year":"2019","unstructured":"Cao ZQ, Wang Z, Leng P. Aberrant N-cadherin expression in cancer. Biomed Pharmacother. 2019;118:109320.","journal-title":"Biomed Pharmacother"},{"issue":"48","key":"5365_CR49","doi-asserted-by":"publisher","first-page":"19204","DOI":"10.1073\/pnas.1108977108","volume":"108","author":"E S\u00e1nchez-Till\u00f3","year":"2011","unstructured":"S\u00e1nchez-Till\u00f3 E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. \u03b2-catenin\/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA. 2011;108(48):19204\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5365_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0502-x","volume":"15","author":"SJ Serrano-Gomez","year":"2016","unstructured":"Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 2016;15:18.","journal-title":"Mol Cancer"},{"issue":"6","key":"5365_CR51","doi-asserted-by":"publisher","first-page":"R217","DOI":"10.1186\/bcr651","volume":"5","author":"PJ Kowalski","year":"2003","unstructured":"Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 2003;5(6):R217\u201322.","journal-title":"Breast Cancer Res"},{"issue":"6","key":"5365_CR52","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.3892\/ol.2017.6063","volume":"13","author":"N Christou","year":"2017","unstructured":"Christou N, Perraud A, Blondy S, Jauberteau MO, Battu S, Mathonnet M. E-cadherin: a potential biomarker of colorectal cancer prognosis. Oncol Lett. 2017;13(6):4571\u20136.","journal-title":"Oncol Lett"},{"key":"5365_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.critrevonc.2017.11.010","volume":"121","author":"SHM Wong","year":"2018","unstructured":"Wong SHM, Fang CM, Chuah LH, Leong CO, Ngai SC. E-cadherin: its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 2018;121:11\u201322.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"5365_CR54","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.devcel.2008.05.009","volume":"14","author":"J Yang","year":"2008","unstructured":"Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818\u201329.","journal-title":"Dev Cell"},{"key":"5365_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010184","author":"K Strouhalova","year":"2020","unstructured":"Strouhalova K, P\u0159echov\u00e1 M, Gandalovi\u010dov\u00e1 A, Br\u00e1bek J, Gregor M, Rosel D. Vimentin intermediate filaments as potential target for cancer treatment. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12010184.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"5365_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cells7100147","volume":"7","author":"F Danielsson","year":"2018","unstructured":"Danielsson F, Peterson MK, Caldeira Ara\u00fajo H, Lautenschl\u00e4ger F, Gad AKB. Vimentin diversity in health and disease. Cells. 2018;7(10):147.","journal-title":"Cells"},{"issue":"18","key":"5365_CR57","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","volume":"68","author":"A Satelli","year":"2011","unstructured":"Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033\u201346.","journal-title":"Cell Mol Life Sci"},{"issue":"19","key":"5365_CR58","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.3390\/cancers13194985","volume":"13","author":"S Usman","year":"2021","unstructured":"Usman S, Waseem NH, Nguyen TKN, Mohsin S, Jamal A, Teh MT, et al. Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis. Cancers (Basel). 2021;13(19):4985.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"5365_CR59","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1101\/gad.1653708","volume":"22","author":"J Andrae","year":"2008","unstructured":"Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276\u2013312.","journal-title":"Genes Dev"},{"key":"5365_CR60","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cytogfr.2021.11.003","volume":"64","author":"E Cecerska-Hery\u0107","year":"2022","unstructured":"Cecerska-Hery\u0107 E, Goszka M, Serwin N, Roszak M, Grygorcewicz B, Hery\u0107 R, et al. Applications of the regenerative capacity of platelets in modern medicine. Cytokine Growth Factor Rev. 2022;64:84\u201394.","journal-title":"Cytokine Growth Factor Rev"},{"key":"5365_CR61","doi-asserted-by":"publisher","first-page":"4708076","DOI":"10.1155\/2017\/4708076","volume":"2017","author":"RM Manzat Saplacan","year":"2017","unstructured":"Manzat Saplacan RM, Balacescu L, Gherman C, Chira RI, Craiu A, Mircea PA, et al. The Role of PDGFs and PDGFRs in Colorectal Cancer. Mediators Inflamm. 2017;2017:4708076.","journal-title":"Mediators Inflamm"},{"issue":"8","key":"5365_CR62","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.molmed.2013.05.002","volume":"19","author":"Y Cao","year":"2013","unstructured":"Cao Y. Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Mol Med. 2013;19(8):460\u201373.","journal-title":"Trends Mol Med"},{"issue":"6","key":"5365_CR63","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ctrv.2012.11.006","volume":"39","author":"Q Wu","year":"2013","unstructured":"Wu Q, Hou X, Xia J, Qian X, Miele L, Sarkar FH, et al. Emerging roles of PDGF-D in EMT progression during tumorigenesis. Cancer Treat Rev. 2013;39(6):640\u20136.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"5365_CR64","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1158\/1078-0432.CCR-10-2456","volume":"17","author":"J Liu","year":"2011","unstructured":"Liu J, Liao S, Huang Y, Samuel R, Shi T, Naxerova K, et al. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res. 2011;17(11):3638\u201348.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5365_CR65","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.bbrc.2016.08.035","volume":"478","author":"H Zhang","year":"2016","unstructured":"Zhang H, Sun JD, Yan LJ, Zhao XP. PDGF-D\/PDGFR\u03b2 promotes tongue squamous carcinoma cell (TSCC) progression via activating p38\/AKT\/ERK\/EMT signal pathway. Biochem Biophys Res Commun. 2016;478(2):845\u201351.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"5365_CR66","first-page":"3577","volume":"12","author":"S Pan","year":"2020","unstructured":"Pan S, Hu Y, Hu M, Jian H, Chen M, Gan L, et al. Platelet-derived PDGF promotes the invasion and metastasis of cholangiocarcinoma by upregulating MMP2\/MMP9 expression and inducing EMT via the p38\/MAPK signalling pathway. Am J Transl Res. 2020;12(7):3577\u201395.","journal-title":"Am J Transl Res"},{"issue":"6","key":"5365_CR67","doi-asserted-by":"publisher","first-page":"9961","DOI":"10.18632\/oncotarget.14283","volume":"8","author":"J Chen","year":"2017","unstructured":"Chen J, Yuan W, Wu L, Tang Q, Xia Q, Ji J, et al. PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1\/Twist1 pathway. Oncotarget. 2017;8(6):9961\u201373.","journal-title":"Oncotarget"},{"issue":"6","key":"5365_CR68","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/cbin.11780","volume":"46","author":"JQ Guo","year":"2022","unstructured":"Guo JQ, Wang CD, Tang HY, Sang BT, Liu X, Yi FP, et al. PDGF-BB\/PDGFR\u03b2 promotes epithelial-mesenchymal transition by affecting PI3K\/AKT\/mTOR-driven aerobic glycolysis in Wilms\u2019 tumor G401 cells. Cell Biol Int. 2022;46(6):907\u201321.","journal-title":"Cell Biol Int"},{"issue":"5","key":"5365_CR69","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021873","volume":"8","author":"M Morikawa","year":"2016","unstructured":"Morikawa M, Derynck R, Miyazono K. TGF-\u03b2 and the TGF-\u03b2 family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 2016;8(5):a021873.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"5365_CR70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1182\/blood.2023022738","volume":"144","author":"L Wang","year":"2024","unstructured":"Wang L, Wang H, Zhu M, Ni X, Sun L, Wang W, et al. Platelet-derived TGF-\u03b21 induces functional reprogramming of myeloid-derived suppressor cells in immune thrombocytopenia. Blood. 2024;144(1):99\u2013112.","journal-title":"Blood"},{"issue":"1","key":"5365_CR71","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1161\/ATVBAHA.124.322029","volume":"45","author":"Y Li","year":"2025","unstructured":"Li Y, Jiang H, Li X, Zhu H, Dai Y, Zhang J, et al. Platelet-Specific Deletion of TGF-\u03b21 Impairs Septic Thrombosis in Mice-Brief Report. Arterioscler Thromb Vasc Biol. 2025;45(1):136\u201343.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5365_CR72","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ceb.2014.09.001","volume":"31","author":"R Derynck","year":"2014","unstructured":"Derynck R, Muthusamy BP, Saeteurn KY. Signaling pathway cooperation in TGF-\u03b2-induced epithelial-mesenchymal transition. Curr Opin Cell Biol. 2014;31:56\u201366.","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"5365_CR73","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/CCO.0b013e32835b6371","volume":"25","author":"Y Katsuno","year":"2013","unstructured":"Katsuno Y, Lamouille S, Derynck R. TGF-\u03b2 signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013;25(1):76\u201384.","journal-title":"Curr Opin Oncol"},{"issue":"570","key":"5365_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aav5183","volume":"12","author":"R Derynck","year":"2019","unstructured":"Derynck R, Budi EH. Specificity, versatility, and control of TGF-\u03b2 family signaling. Sci Signal. 2019;12(570):eaav5183.","journal-title":"Sci Signal"},{"issue":"17","key":"5365_CR75","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1038\/sj.emboj.7601818","volume":"26","author":"MK Lee","year":"2007","unstructured":"Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J, et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. Embo j. 2007;26(17):3957\u201367.","journal-title":"Embo j"},{"issue":"8","key":"5365_CR76","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1158\/0008-5472.CAN-06-3851","volume":"67","author":"AJ Galliher","year":"2007","unstructured":"Galliher AJ, Schiemann WP. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res. 2007;67(8):3752\u20138.","journal-title":"Cancer Res"},{"issue":"6","key":"5365_CR77","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.devcel.2021.02.028","volume":"56","author":"Y Katsuno","year":"2021","unstructured":"Katsuno Y, Derynck R. Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-\u03b2 family. Dev Cell. 2021;56(6):726\u201346.","journal-title":"Dev Cell"},{"key":"5365_CR78","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1749-6632.2000.tb06549.x","volume":"905","author":"EJ Goetzl","year":"2000","unstructured":"Goetzl EJ, Lee H, Dolezalova H, Kalli KR, Conover CA, Hu YL, et al. Mechanisms of lysolipid phosphate effects on cellular survival and proliferation. Ann N Y Acad Sci. 2000;905:177\u201387.","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"5365_CR79","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc1143","volume":"3","author":"GB Mills","year":"2003","unstructured":"Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003;3(8):582\u201391.","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"5365_CR80","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1111\/bph.14362","volume":"175","author":"R Leblanc","year":"2018","unstructured":"Leblanc R, Houssin A, Peyruchaud O. Platelets, autotaxin and lysophosphatidic acid signalling: win-win factors for cancer metastasis. Br J Pharmacol. 2018;175(15):3100\u201310.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"5365_CR81","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1476-5381.2011.01622.x","volume":"165","author":"T Mutoh","year":"2012","unstructured":"Mutoh T, Rivera R, Chun J. Insights into the pharmacological relevance of lysophospholipid receptors. Br J Pharmacol. 2012;165(4):829\u201344.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"5365_CR82","first-page":"67","volume":"44","author":"Z Ren","year":"2019","unstructured":"Ren Z, Zhang C, Ma L, Zhang X, Shi S, Tang D, et al. Lysophosphatidic acid induces the migration and invasion of SGC-7901 gastric cancer cells through the LPA2 and Notch signaling pathways. Int J Mol Med. 2019;44(1):67\u201378.","journal-title":"Int J Mol Med"},{"issue":"36","key":"5365_CR83","doi-asserted-by":"publisher","first-page":"22143","DOI":"10.1074\/jbc.M115.641092","volume":"290","author":"RJ Burkhalter","year":"2015","unstructured":"Burkhalter RJ, Westfall SD, Liu Y, Stack MS. Lysophosphatidic acid initiates epithelial to mesenchymal transition and induces \u03b2-Catenin-mediated transcription in epithelial ovarian carcinoma. J Biol Chem. 2015;290(36):22143\u201354.","journal-title":"J Biol Chem"},{"issue":"18","key":"5365_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810497","volume":"23","author":"GH Lee","year":"2022","unstructured":"Lee GH, Cheon J, Kim D, Jun HS. Lysophosphatidic acid promotes epithelial-mesenchymal transition in kidney epithelial cells via the LPAR1\/MAPK-AKT\/KLF5 signaling pathway in diabetic nephropathy. Int J Mol Sci. 2022;23(18):10497.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5365_CR85","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576\u201390.","journal-title":"Cancer Cell"},{"issue":"4","key":"5365_CR86","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/19336918.2015.1016686","volume":"9","author":"W Xu","year":"2015","unstructured":"Xu W, Yang Z, Lu N. A new role for the PI3K\/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adhes Migr. 2015;9(4):317\u201324.","journal-title":"Cell Adhes Migr"},{"key":"5365_CR87","doi-asserted-by":"publisher","first-page":"12465","DOI":"10.1038\/srep12465","volume":"5","author":"GB Jang","year":"2015","unstructured":"Jang GB, Kim JY, Cho SD, Park KS, Jung JY, Lee HY, et al. Blockade of Wnt\/\u03b2-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. Sci Rep. 2015;5:12465.","journal-title":"Sci Rep"},{"issue":"1","key":"5365_CR88","first-page":"1","volume":"25","author":"J Yin","year":"2021","unstructured":"Yin J, Guo Y, Li Z. Platelet-derived growth factor-B signalling might promote epithelial-mesenchymal transition in gastric carcinoma cells through activation of the MAPK\/ERK pathway. Contemp Oncol (Pozn). 2021;25(1):1\u20136.","journal-title":"Contemp Oncol (Pozn)"},{"key":"5365_CR89","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.thromres.2019.02.026","volume":"177","author":"S Asghar","year":"2019","unstructured":"Asghar S, Parvaiz F, Manzoor S. Multifaceted role of cancer educated platelets in survival of cancer cells. Thromb Res. 2019;177:42\u201350.","journal-title":"Thromb Res"},{"issue":"6","key":"5365_CR90","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","volume":"33","author":"M Haemmerle","year":"2018","unstructured":"Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell. 2018;33(6):965\u201383.","journal-title":"Cancer Cell"},{"issue":"8","key":"5365_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073609","volume":"8","author":"S Takagi","year":"2013","unstructured":"Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, et al. Platelets promote tumor growth and metastasis via direct interaction between Aggrus\/podoplanin and CLEC-2. PLoS ONE. 2013;8(8):e73609.","journal-title":"PLoS ONE"},{"issue":"8","key":"5365_CR92","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1046\/j.1538-7836.2003.00344.x","volume":"1","author":"J Folkman","year":"2003","unstructured":"Folkman J. Angiogenesis and proteins of the hemostatic system. J Thromb Haemost. 2003;1(8):1681\u20132.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"5365_CR93","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/74651","volume":"6","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6(4):389\u201395.","journal-title":"Nat Med"},{"issue":"6","key":"5365_CR94","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00262-020-02758-7","volume":"70","author":"V Dymicka-Piekarska","year":"2021","unstructured":"Dymicka-Piekarska V, Koper-Lenkiewicz OM, Zi\u0144czuk J, Kratz E, Kami\u0144ska J. Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TAPs). Cancer Immunol Immunother. 2021;70(6):1497\u2013510.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"5365_CR95","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.gde.2009.04.002","volume":"19","author":"S Wang","year":"2009","unstructured":"Wang S, Olson EN. AngiomiRs\u2013key regulators of angiogenesis. Curr Opin Genet Dev. 2009;19(3):205\u201311.","journal-title":"Curr Opin Genet Dev"},{"issue":"6","key":"5365_CR96","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/cancers10060185","volume":"10","author":"M Tauro","year":"2018","unstructured":"Tauro M, Lynch CC. Cutting to the chase: how matrix metalloproteinase-2 activity controls breast-cancer-to-bone metastasis. Cancers (Basel). 2018;10(6):185.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"5365_CR97","first-page":"241","volume":"17","author":"ZH Li","year":"2019","unstructured":"Li ZH, Zhou Y, Ding YX, Guo QL, Zhao L. Roles of integrin in tumor development and the target inhibitors. Chin J Nat Med. 2019;17(4):241\u201351.","journal-title":"Chin J Nat Med"},{"issue":"1","key":"5365_CR98","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13578-020-00416-0","volume":"10","author":"F Xu","year":"2020","unstructured":"Xu F, Na L, Li Y, Chen L. Roles of the PI3K\/AKT\/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci. 2020;10(1):54.","journal-title":"Cell Biosci"},{"issue":"15","key":"5365_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155195","volume":"21","author":"M \u017bmigrodzka","year":"2020","unstructured":"\u017bmigrodzka M, Witkowska-Pi\u0142aszewicz O, Winnicka A. Platelets extracellular vesicles as regulators of cancer progression-an updated perspective. Int J Mol Sci. 2020;21(15):5195.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5365_CR100","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.annonc.2020.02.012","volume":"31","author":"C Bosetti","year":"2020","unstructured":"Bosetti C, Santucci C, Gallus S, Martinetti M, La Vecchia C. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Ann Oncol. 2020;31(5):558\u201368.","journal-title":"Ann Oncol"},{"issue":"9","key":"5365_CR101","doi-asserted-by":"publisher","first-page":"822","DOI":"10.2174\/1568026615666150220111942","volume":"15","author":"M Ciacciarelli","year":"2015","unstructured":"Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem. 2015;15(9):822\u20139.","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"5365_CR102","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/cancers6010436","volume":"6","author":"AM Fajardo","year":"2014","unstructured":"Fajardo AM, Piazza GA, Tinsley HN. The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment. Cancers (Basel). 2014;6(1):436\u201358.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"5365_CR103","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1002\/jcb.24237","volume":"113","author":"JC Wong","year":"2012","unstructured":"Wong JC, Bathina M, Fiscus RR. Cyclic GMP\/protein kinase G type-I\u03b1 (PKG-I\u03b1) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-I\u03b1 kinase activity synergizes with cisplatin in non-small cell lung cancer cells. J Cell Biochem. 2012;113(11):3587\u201398.","journal-title":"J Cell Biochem"},{"issue":"7","key":"5365_CR104","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/j.1538-7836.2007.02537.x","volume":"5","author":"YQ Ma","year":"2007","unstructured":"Ma YQ, Qin J, Plow EF. Platelet integrin alpha(IIb)beta(3): activation mechanisms. J Thromb Haemost. 2007;5(7):1345\u201352.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"5365_CR105","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-0035-1564835","volume":"42","author":"T Gremmel","year":"2016","unstructured":"Gremmel T, Frelinger AL 3rd, Michelson AD. Platelet physiology. Semin Thromb Hemost. 2016;42(3):191\u2013204.","journal-title":"Semin Thromb Hemost"},{"key":"5365_CR106","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.13283.1","volume":"7","author":"A Sharda","year":"2018","unstructured":"Sharda A, Flaumenhaft R. The life cycle of platelet granules. F1000Res. 2018;7:236.","journal-title":"F1000Res"},{"issue":"14","key":"5365_CR107","doi-asserted-by":"publisher","first-page":"5623","DOI":"10.1158\/0008-5472.CAN-09-1370","volume":"69","author":"B Ho-Tin-No\u00e9","year":"2009","unstructured":"Ho-Tin-No\u00e9 B, Goerge T, Wagner DD. Platelets: guardians of tumor vasculature. Cancer Res. 2009;69(14):5623\u20136.","journal-title":"Cancer Res"},{"issue":"16","key":"5365_CR108","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.1158\/0008-5472.CAN-08-0718","volume":"68","author":"B Ho-Tin-No\u00e9","year":"2008","unstructured":"Ho-Tin-No\u00e9 B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res. 2008;68(16):6851\u20138.","journal-title":"Cancer Res"},{"issue":"5","key":"5365_CR109","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/md23050212","volume":"23","author":"AW Akram","year":"2025","unstructured":"Akram AW, Choi DC, Chae HK, Kim SD, Kwak D, Yun BS, et al. Dihydrogeodin from Fennellia flavipes Modulates Platelet Aggregation via Downregulation of Calcium Signaling, \u03b1IIb\u03b2(3) Integrins, MAPK, and PI3K\/Akt Pathways. Mar Drugs. 2025;23(5):212.","journal-title":"Mar Drugs"},{"issue":"4","key":"5365_CR110","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jgr.2025.04.002","volume":"49","author":"AW Akram","year":"2025","unstructured":"Akram AW, Shin JH, Batmunkh U, Saba E, Kang YM, Jung S, et al. Ginsenoside Rg5 inhibits platelet aggregation by regulating GPVI signaling pathways and ferric chloride-induced thrombosis. J Ginseng Res. 2025;49(4):460\u20139.","journal-title":"J Ginseng Res"},{"key":"5365_CR111","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/9927160","volume":"2024","author":"AW Akram","year":"2024","unstructured":"Akram AW, Saba E, Rhee MH. Antiplatelet and antithrombotic activities of Lespedeza cuneata via pharmacological inhibition of integrin \u03b1IIb\u03b23, MAPK, and PI3K\/AKT pathways and FeCl3-induced murine thrombosis. Evid Based Complement Alternat Med. 2024;2024:9927160.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"12","key":"5365_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13122924","volume":"13","author":"AW Akram","year":"2025","unstructured":"Akram AW, Lee GH, Baek SM, Kang J, Koo Y, Oh Y, et al. Xanthium strumarium L. exhibits potent antiplatelet and antithrombotic effects by modulating MAPK and PI3K\/AKT signaling pathways and inhibiting ferric chloride-induced thrombosis. Biomedicines. 2025;13(12):2924.","journal-title":"Biomedicines"},{"issue":"3","key":"5365_CR113","doi-asserted-by":"publisher","first-page":"s39","DOI":"10.1161\/ATVBAHA.107.160226","volume":"28","author":"HH Kim","year":"2008","unstructured":"Kim HH, Liao JK. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol. 2008;28(3):s39-42.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"5365_CR114","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","volume":"13","author":"DH Maurice","year":"2014","unstructured":"Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014;13(4):290\u2013314.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"5365_CR115","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.coph.2011.10.003","volume":"11","author":"I Levy","year":"2011","unstructured":"Levy I, Horvath A, Azevedo M, de Alexandre RB, Stratakis CA. Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment. Curr Opin Pharmacol. 2011;11(6):689\u201397.","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"5365_CR116","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","volume":"100","author":"K Omori","year":"2007","unstructured":"Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res. 2007;100(3):309\u201327.","journal-title":"Circ Res"},{"key":"5365_CR117","first-page":"1","volume":"63","author":"M Conti","year":"1999","unstructured":"Conti M, Jin SL. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol. 1999;63:1\u201338.","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"5365_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1165989","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y, Wang H, Zhao Z, Yang Y, Meng Z, Qin L. Effects of the interactions between platelets with other cells in tumor growth and progression. Front Immunol. 2023;14:1165989.","journal-title":"Front Immunol"},{"issue":"9","key":"5365_CR119","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/CAD.0b013e32833ddba6","volume":"21","author":"S Choudhary","year":"2010","unstructured":"Choudhary S, Rathore K, Wang HC. FK228 and oncogenic H-Ras synergistically induce Mek1\/2 and Nox-1 to generate reactive oxygen species for differential cell death. Anticancer Drugs. 2010;21(9):831\u201340.","journal-title":"Anticancer Drugs"},{"issue":"12","key":"5365_CR120","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1093\/carcin\/23.12.2123","volume":"23","author":"M Yu","year":"2002","unstructured":"Yu M, Snyderwine EG. H-ras oncogene mutations during development of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced rat mammary gland cancer. Carcinogenesis. 2002;23(12):2123\u20138.","journal-title":"Carcinogenesis"},{"issue":"1","key":"5365_CR121","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1152\/physrev.00044.2005","volume":"87","author":"K Bedard","year":"2007","unstructured":"Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87(1):245\u2013313.","journal-title":"Physiol Rev"},{"issue":"1","key":"5365_CR122","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1038\/s41467-020-17873-3","volume":"11","author":"R Hoefflin","year":"2020","unstructured":"Hoefflin R, Harlander S, Sch\u00e4fer S, Metzger P, Kuo F, Sch\u00f6nenberger D, et al. HIF-1\u03b1 and HIF-2\u03b1 differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nat Commun. 2020;11(1):4111.","journal-title":"Nat Commun"},{"issue":"35","key":"5365_CR123","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1038\/onc.2011.568","volume":"31","author":"TI Hsu","year":"2012","unstructured":"Hsu TI, Wang MC, Chen SY, Yeh YM, Su WC, Chang WC, et al. Sp1 expression regulates lung tumor progression. Oncogene. 2012;31(35):3973\u201388.","journal-title":"Oncogene"},{"issue":"3","key":"5365_CR124","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10555-006-9005-3","volume":"25","author":"F Balkwill","year":"2006","unstructured":"Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25(3):409\u201316.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"5365_CR125","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/imm.13016","volume":"156","author":"CG Bazewicz","year":"2019","unstructured":"Bazewicz CG, Dinavahi SS, Schell TD, Robertson GP. Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancer. Immunology. 2019;156(1):47\u201355.","journal-title":"Immunology"},{"issue":"2","key":"5365_CR126","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/(SICI)1097-0215(20000115)85:2%3C176::AID-IJC5%3E3.0.CO;2-E","volume":"85","author":"A Moon","year":"2000","unstructured":"Moon A, Kim MS, Kim TG, Kim SH, Kim HE, Chen YQ, et al. H-ras, but not N-ras, induces an invasive phenotype in human breast epithelial cells: a role for MMP-2 in the H-ras-induced invasive phenotype. Int J Cancer. 2000;85(2):176\u201381.","journal-title":"Int J Cancer"},{"issue":"3","key":"5365_CR127","first-page":"790","volume":"6","author":"RS Herbst","year":"2000","unstructured":"Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, et al. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res. 2000;6(3):790\u20137.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"5365_CR128","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/carcin\/bgs097","volume":"33","author":"S Choudhary","year":"2012","unstructured":"Choudhary S, Sood S, Donnell RL, Wang H-CR. Intervention of human breast cell carcinogenesis chronically induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Carcinogenesis. 2012;33(4):876\u201385.","journal-title":"Carcinogenesis"},{"issue":"5600","key":"5365_CR129","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1126\/science.1072682","volume":"298","author":"GL Johnson","year":"2002","unstructured":"Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911\u20132.","journal-title":"Science"},{"issue":"10","key":"5365_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.547","volume":"8","author":"W Sheng","year":"2017","unstructured":"Sheng W, Chen C, Dong M, Wang G, Zhou J, Song H, et al. Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via integrin\/EGFR-ERK\/MAPK signaling pathway. Cell Death Dis. 2017;8(10):e3147.","journal-title":"Cell Death Dis"},{"issue":"21","key":"5365_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215282","volume":"15","author":"J Shi","year":"2023","unstructured":"Shi J, Li W, Jia Z, Peng Y, Hou J, Li N, et al. Synaptotagmin 1 suppresses colorectal cancer metastasis by inhibiting ERK\/MAPK signaling-mediated tumor cell pseudopodial formation and migration. Cancers (Basel). 2023;15(21):5282.","journal-title":"Cancers (Basel)"},{"issue":"Pt 20","key":"5365_CR132","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1242\/jcs.01481","volume":"117","author":"C Huang","year":"2004","unstructured":"Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci. 2004;117(Pt 20):4619\u201328.","journal-title":"J Cell Sci"},{"issue":"4","key":"5365_CR133","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1046\/j.1523-1755.2001.00933.x","volume":"60","author":"KY Hung","year":"2001","unstructured":"Hung KY, Chen CT, Huang JW, Lee PH, Tsai TJ, Hsieh BS. Dipyridamole inhibits TGF-beta-induced collagen gene expression in human peritoneal mesothelial cells. Kidney Int. 2001;60(4):1249\u201357.","journal-title":"Kidney Int"},{"issue":"3","key":"5365_CR134","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1046\/j.1523-1755.2001.060003872.x","volume":"60","author":"KY Hung","year":"2001","unstructured":"Hung KY, Chen CT, Yen CJ, Lee PH, Tsai TJ, Hsieh BS. Dipyridamole inhibits PDGF-stimulated human peritoneal mesothelial cell proliferation. Kidney Int. 2001;60(3):872\u201381.","journal-title":"Kidney Int"},{"issue":"2","key":"5365_CR135","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1124\/jpet.105.089987","volume":"315","author":"S Chakrabarti","year":"2005","unstructured":"Chakrabarti S, Vitseva O, Iyu D, Varghese S, Freedman JE. The effect of dipyridamole on vascular cell-derived reactive oxygen species. J Pharmacol Exp Ther. 2005;315(2):494\u2013500.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"5365_CR136","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0922-4106(92)90157-Q","volume":"227","author":"S Suzuki","year":"1992","unstructured":"Suzuki S, Sugai K, Sato H, Sakatume M, Arakawa M. Inhibition of active oxygen generation by dipyridamole in human polymorphonuclear leukocytes. Eur J Pharmacol. 1992;227(4):395\u2013401.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"5365_CR137","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0891-5849(96)00488-1","volume":"22","author":"L Iuliano","year":"1997","unstructured":"Iuliano L, Colavita AR, Leo R, Pratic\u00f2 D, Violi F. Oxygen free radicals and platelet activation. Free Radic Biol Med. 1997;22(6):999\u20131006.","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"5365_CR138","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0049-3848(92)90278-I","volume":"66","author":"JP De la Cruz","year":"1992","unstructured":"De la Cruz JP, Garc\u00eda PJ, S\u00e1nchez de la Cuesta F. Dipyridamole inhibits platelet aggregation induced by oxygen-derived free radicals. Thromb Res. 1992;66(4):277\u201385.","journal-title":"Thromb Res"},{"issue":"3","key":"5365_CR139","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/mc.21970","volume":"53","author":"S Choudhary","year":"2014","unstructured":"Choudhary S, Sood S, Wang HC. Dipyridamole intervention of breast cell carcinogenesis. Mol Carcinog. 2014;53(3):243\u201352.","journal-title":"Mol Carcinog"},{"issue":"2","key":"5365_CR140","first-page":"88","volume":"11","author":"N Morisaki","year":"1982","unstructured":"Morisaki N, Stitts JM, Bartels-Tomei L, Milo GE, Panganamala RV, Cornwell DG. Dipyridamole: an antioxidant that promotes the proliferation of aorta smooth muscle cells. Artery. 1982;11(2):88\u2013107.","journal-title":"Artery"},{"issue":"8399","key":"5365_CR141","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(84)90582-8","volume":"2","author":"H Deckmyn","year":"1984","unstructured":"Deckmyn H, Gresele P, Arnout J, Todisco A, Vermylen J. Prolonging prostacyclin production by nafazatrom or dipyridamole. Lancet. 1984;2(8399):410\u20131.","journal-title":"Lancet"},{"issue":"2","key":"5365_CR142","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1055\/s-0038-1651103","volume":"57","author":"P Gresele","year":"1987","unstructured":"Gresele P, Arnout J, Vermylen J. Dipyridamole inhibits leukotriene B4 synthesis. Thromb Haemost. 1987;57(2):235.","journal-title":"Thromb Haemost"},{"issue":"1","key":"5365_CR143","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10585-012-9506-0","volume":"30","author":"D Spano","year":"2013","unstructured":"Spano D, Marshall JC, Marino N, De Martino D, Romano A, Scoppettuolo MN, et al. Dipyridamole prevents triple-negative breast-cancer progression. Clin Exp Metastasis. 2013;30(1):47\u201368.","journal-title":"Clin Exp Metastasis"},{"issue":"5","key":"5365_CR144","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10557-005-4659-6","volume":"19","author":"W Schaper","year":"2005","unstructured":"Schaper W. Dipyridamole, an underestimated vascular protective drug. Cardiovasc Drugs Ther. 2005;19(5):357\u201363.","journal-title":"Cardiovasc Drugs Ther"},{"key":"5365_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113747","volume":"172","author":"A Vlachodimou","year":"2020","unstructured":"Vlachodimou A, Konstantinopoulou K, Ap IJ, Heitman LH. Affinity, binding kinetics and functional characterization of Draflazine analogues for human equilibrative nucleoside transporter 1 (SLC29A1). Biochem Pharmacol. 2020;172:113747.","journal-title":"Biochem Pharmacol"},{"key":"5365_CR146","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0065-2571(93)90021-5","volume":"33","author":"JA Belt","year":"1993","unstructured":"Belt JA, Marina NM, Phelps DA, Crawford CR. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul. 1993;33:235\u201352.","journal-title":"Adv Enzyme Regul"},{"issue":"1","key":"5365_CR147","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10637-005-4541-1","volume":"24","author":"J Walling","year":"2006","unstructured":"Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs. 2006;24(1):37\u201377.","journal-title":"Invest New Drugs"},{"key":"5365_CR148","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/jcb.240630512","volume":"24","author":"MP Dearing","year":"1996","unstructured":"Dearing MP, Englee-Miller MJ, Kratzke RA, Kramer BS, Chu E, Weinstein J, et al. Dipyridamole mediated enhanced antiproliferative activity of 10-ethyl-10-deazaaminopterin (10-EDAM) against human lung cancer cell lines. J Cell Biochem Suppl. 1996;24:165\u201372.","journal-title":"J Cell Biochem Suppl"},{"issue":"1","key":"5365_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.06.001","volume":"382","author":"MP Thom\u00e9","year":"2019","unstructured":"Thom\u00e9 MP, Pereira LC, Onzi GR, Rohden F, Ilha M, Guma FT, et al. Dipyridamole impairs autophagic flux and exerts antiproliferative activity on prostate cancer cells. Exp Cell Res. 2019;382(1):111456.","journal-title":"Exp Cell Res"},{"issue":"4","key":"5365_CR150","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s13402-023-00789-7","volume":"46","author":"S Huang","year":"2023","unstructured":"Huang S, Zhang NQ, Xu CJ, Huang WQ, Li DX, Li J, et al. Dipyridamole enhances the anti-cancer ability of aspirin against colorectal cancer by inducing apoptosis in an unfolded protein response-dependent manner. Cell Oncol (Dordr). 2023;46(4):953\u201367.","journal-title":"Cell Oncol (Dordr)"},{"issue":"5","key":"5365_CR151","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1189\/jlb.0609385","volume":"86","author":"G Solinas","year":"2009","unstructured":"Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86(5):1065\u201373.","journal-title":"J Leukoc Biol"},{"issue":"5","key":"5365_CR152","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"key":"5365_CR153","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.phrs.2014.05.008","volume":"87","author":"P Balakumar","year":"2014","unstructured":"Balakumar P, Nyo YH, Renushia R, Raaginey D, Oh AN, Varatharajan R, et al. Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? Pharmacol Res. 2014;87:144\u201350.","journal-title":"Pharmacol Res"},{"issue":"1","key":"5365_CR154","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13046-022-02578-w","volume":"42","author":"M Keller","year":"2023","unstructured":"Keller M, Rohlf K, Glotzbach A, Leonhardt G, L\u00fcke S, Derksen K, et al. Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth. J Exp Clin Cancer Res. 2023;42(1):25.","journal-title":"J Exp Clin Cancer Res"},{"key":"5365_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115376","volume":"207","author":"J Gao","year":"2023","unstructured":"Gao J, Zhou C, Zhong Y, Shi L, Luo X, Su H, et al. Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines. Biochem Pharmacol. 2023;207:115376.","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"5365_CR156","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/1097-0142(19930415)71:8<2466::AID-CNCR2820710807>3.0.CO;2-Q","volume":"71","author":"GN Tzanakakis","year":"1993","unstructured":"Tzanakakis GN, Agarwal KC, Vezeridis MP. Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233. Cancer. 1993;71(8):2466\u201371.","journal-title":"Cancer"},{"issue":"4","key":"5365_CR157","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000129103","volume":"22","author":"Y Sakaguchi","year":"1990","unstructured":"Sakaguchi Y, Emi Y, Maehara Y, Kohnoe S, Sugimachi K. Combined treatment of adriamycin and dipyridamole inhibits lung metastasis of B16 melanoma cells in mice. Eur Surg Res. 1990;22(4):213\u20138.","journal-title":"Eur Surg Res"},{"issue":"1","key":"5365_CR158","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1158\/1535-7163.MCT-19-0413","volume":"19","author":"S Zhou","year":"2020","unstructured":"Zhou S, Xu H, Tang Q, Xia H, Bi F. Dipyridamole enhances the cytotoxicities of Trametinib against colon cancer cells through combined targeting of HMGCS1 and MEK pathway. Mol Cancer Ther. 2020;19(1):135\u201346.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"5365_CR159","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1158\/1078-0432.CCR-17-2776","volume":"24","author":"RR Mishra","year":"2018","unstructured":"Mishra RR, Belder N, Ansari SA, Kayhan M, Bal H, Raza U, et al. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer. Clin Cancer Res. 2018;24(8):1987\u20132001.","journal-title":"Clin Cancer Res"},{"key":"5365_CR160","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.molmet.2019.04.003","volume":"25","author":"J Longo","year":"2019","unstructured":"Longo J, Mullen PJ, Yu R, van Leeuwen JE, Masoomian M, Woon DTS, et al. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. Mol Metab. 2019;25:119\u201330.","journal-title":"Mol Metab"},{"issue":"9","key":"5365_CR161","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.25122\/jml-2021-0199","volume":"15","author":"E Alyasiry","year":"2022","unstructured":"Alyasiry E, Janabi A, Hadi N. Dipyridamole ameliorates doxorubicin-induced cardiotoxicity. J Med Life. 2022;15(9):1184\u201390.","journal-title":"J Med Life"},{"issue":"3","key":"5365_CR162","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/0163-7258(89)90084-3","volume":"40","author":"JL Grem","year":"1989","unstructured":"Grem JL, Fischer PH. Enhancement of 5-fluorouracil\u2019s anticancer activity by dipyridamole. Pharmacol Ther. 1989;40(3):349\u201371.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"5365_CR163","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00001813-200201000-00003","volume":"13","author":"CR Boyer","year":"2002","unstructured":"Boyer CR, Karjian PL, Wahl GM, Pegram M, Neuteboom ST. Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011. Anticancer Drugs. 2002;13(1):29\u201336.","journal-title":"Anticancer Drugs"},{"issue":"6","key":"5365_CR164","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/0006-2952(87)90168-7","volume":"36","author":"TJ Van Mouwerik","year":"1987","unstructured":"Van Mouwerik TJ, Pangallo CA, Willson JK, Fischer PH. Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole. Biochem Pharmacol. 1987;36(6):809\u201314.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"5365_CR165","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s002800050022","volume":"45","author":"NL Lehman","year":"2000","unstructured":"Lehman NL, Danenberg PV. Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: implications for chemotherapy. Cancer Chemother Pharmacol. 2000;45(2):142\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"5365_CR166","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1002\/1878-0261.12775","volume":"14","author":"J Longo","year":"2020","unstructured":"Longo J, Pandyra AA, Stachura P, Minden MD, Schimmer AD, Penn LZ. Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. Mol Oncol. 2020;14(10):2533\u201345.","journal-title":"Mol Oncol"},{"issue":"4-6","key":"5365_CR167","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.vph.2007.12.004","volume":"48","author":"S Chakrabarti","year":"2008","unstructured":"Chakrabarti S, Freedman JE. Dipyridamole, cerebrovascular disease, and the vasculature. Vascul Pharmacol. 2008;48(4\u20136):143\u20139.","journal-title":"Vascul Pharmacol"},{"issue":"8","key":"5365_CR168","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1468-2982.2006.01137.x","volume":"26","author":"C Kruuse","year":"2006","unstructured":"Kruuse C, Lassen LH, Iversen HK, Oestergaard S, Olesen J. Dipyridamole may induce migraine in patients with migraine without aura. Cephalalgia. 2006;26(8):925\u201333.","journal-title":"Cephalalgia"},{"key":"5365_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708.","journal-title":"Biomed Pharmacother"},{"key":"5365_CR170","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.lfs.2018.03.023","volume":"200","author":"A Pugazhendhi","year":"2018","unstructured":"Pugazhendhi A, Edison T, Velmurugan BK, Jacob JA, Karuppusamy I. Toxicity of doxorubicin (Dox) to different experimental organ systems. Life Sci. 2018;200:26\u201330.","journal-title":"Life Sci"},{"issue":"1","key":"5365_CR171","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/bip.10319","volume":"69","author":"SB Howerton","year":"2003","unstructured":"Howerton SB, Nagpal A, Williams LD. Surprising roles of electrostatic interactions in DNA-ligand complexes. Biopolymers. 2003;69(1):87\u201399.","journal-title":"Biopolymers"},{"key":"5365_CR172","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7582730","volume":"2018","author":"S Gorini","year":"2018","unstructured":"Gorini S, De Angelis A, Berrino L, Malara N, Rosano G, Ferraro E. Chemotherapeutic drugs and mitochondrial dysfunction: focus on Doxorubicin, Trastuzumab, and Sunitinib. Oxid Med Cell Longev. 2018;2018:7582730.","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"5365_CR173","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/jor.20169","volume":"24","author":"DE Joyner","year":"2006","unstructured":"Joyner DE, Bastar JD, Randall RL. Doxorubicin induces cell senescence preferentially over apoptosis in the FU-SY-1 synovial sarcoma cell line. J Orthop Res. 2006;24(6):1163\u20139.","journal-title":"J Orthop Res"},{"issue":"1","key":"5365_CR174","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1021\/ar800114w","volume":"42","author":"BG V\u00e9rtessy","year":"2009","unstructured":"V\u00e9rtessy BG, T\u00f3th J. Keeping uracil out of DNA: physiological role, structure and catalytic mechanism of dUTPases. Acc Chem Res. 2009;42(1):97\u2013106.","journal-title":"Acc Chem Res"},{"issue":"2","key":"5365_CR175","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.phrs.2005.10.004","volume":"53","author":"K Djazayeri","year":"2006","unstructured":"Djazayeri K, Szilv\u00e1ssy Z, Benko K, R\u00f3zsa B, Szab\u00f3 B, Szentmikl\u00f3si AJ, et al. Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil. Pharmacol Res. 2006;53(2):156\u201361.","journal-title":"Pharmacol Res"},{"issue":"5","key":"5365_CR176","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1188\/14.CJON.581-585","volume":"18","author":"J Latchman","year":"2014","unstructured":"Latchman J, Guastella A, Tofthagen C. 5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice. Clin J Oncol Nurs. 2014;18(5):581\u20135.","journal-title":"Clin J Oncol Nurs"},{"issue":"1","key":"5365_CR177","first-page":"65","volume":"38","author":"RW Nelson","year":"1981","unstructured":"Nelson RW, Frank JT. Intrathecal methotrexate-induced neurotoxicities. Am J Hosp Pharm. 1981;38(1):65\u20138.","journal-title":"Am J Hosp Pharm"},{"issue":"4","key":"5365_CR178","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0889-857X(05)70358-6","volume":"23","author":"BN Cronstein","year":"1997","unstructured":"Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am. 1997;23(4):739\u201355.","journal-title":"Rheum Dis Clin North Am"},{"key":"5365_CR179","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-319-91442-8_7","volume":"211","author":"R Zeiser","year":"2018","unstructured":"Zeiser R, Andrlov\u00e1 H, Meiss F. Trametinib (GSK1120212). Recent Results Cancer Res. 2018;211:91\u2013100.","journal-title":"Recent Results Cancer Res"},{"key":"5365_CR180","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-3-642-54490-3_15","volume":"201","author":"R Zeiser","year":"2014","unstructured":"Zeiser R. Trametinib. Recent Results Cancer Res. 2014;201:241\u20138.","journal-title":"Recent Results Cancer Res"},{"issue":"5\u20136","key":"5365_CR181","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/15384047.2021.1919004","volume":"22","author":"M Elbadawy","year":"2021","unstructured":"Elbadawy M, Sato Y, Mori T, Goto Y, Hayashi K, Yamanaka M, et al. Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism. Cancer Biol Ther. 2021;22(5\u20136):357\u201371.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"5365_CR182","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12348-023-00339-0","volume":"13","author":"B Tar\u0131m","year":"2023","unstructured":"Tar\u0131m B, K\u0131l\u0131\u00e7 M. Ocular side effects of Trametinib and Dabrafenib: a case report. J Ophthalmic Inflamm Infect. 2023;13(1):17.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"5365_CR183","first-page":"1","volume":"21","author":"SP Ackland","year":"2003","unstructured":"Ackland SP, Beale P, Peters GJ. Thymidylate synthase inhibitors. Cancer Chemother Biol Response Modif. 2003;21:1\u201328.","journal-title":"Cancer Chemother Biol Response Modif"},{"issue":"7\u20138","key":"5365_CR184","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/0959-8049(95)00166-G","volume":"31a","author":"AL Jackman","year":"1995","unstructured":"Jackman AL, Farrugia DC, Gibson W, Kimbell R, Harrap KR, Stephens TC, et al. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer. 1995;31a(7\u20138):1277\u201382.","journal-title":"Eur J Cancer"},{"issue":"10","key":"5365_CR185","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1586\/era.11.136","volume":"11","author":"VF Surmont","year":"2011","unstructured":"Surmont VF, van Meerbeeck JP. Raltitrexed in mesothelioma. Expert Rev Anticancer Ther. 2011;11(10):1481\u201390.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"5365_CR186","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2183\/pjab.84.189","volume":"84","author":"T Tsuruo","year":"2008","unstructured":"Tsuruo T, Fujita N. Platelet aggregation in the formation of tumor metastasis. Proc Jpn Acad Ser B Phys Biol Sci. 2008;84(6):189\u201398.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"8","key":"5365_CR187","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nm1469","volume":"12","author":"PS Steeg","year":"2006","unstructured":"Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895\u2013904.","journal-title":"Nat Med"},{"issue":"9","key":"5365_CR188","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12032-014-0024-6","volume":"31","author":"Q Dang","year":"2014","unstructured":"Dang Q, Liu J, Li J, Sun Y. Podoplanin: a novel regulator of tumor invasion and metastasis. Med Oncol. 2014;31(9):24.","journal-title":"Med Oncol"},{"issue":"11","key":"5365_CR189","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/nm.3391","volume":"19","author":"L Wan","year":"2013","unstructured":"Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013;19(11):1450\u201364.","journal-title":"Nat Med"},{"issue":"6","key":"5365_CR190","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/10408363.2016.1200008","volume":"53","author":"XR Xu","year":"2016","unstructured":"Xu XR, Zhang D, Oswald BE, Carrim N, Wang X, Hou Y, et al. Platelets are versatile cells: new discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond. Crit Rev Clin Lab Sci. 2016;53(6):409\u201330.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"7648","key":"5365_CR191","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature21706","volume":"544","author":"E Lefrancais","year":"2017","unstructured":"Lefrancais E, Ortiz-Munoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017;544(7648):105\u20139.","journal-title":"Nature"},{"issue":"4","key":"5365_CR192","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc2618","volume":"9","author":"JA Joyce","year":"2009","unstructured":"Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239\u201352.","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"5365_CR193","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1158\/0008-5472.CAN-12-1223","volume":"72","author":"D Gao","year":"2012","unstructured":"Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res. 2012;72(19):4883\u20139.","journal-title":"Cancer Res"},{"issue":"6","key":"5365_CR194","first-page":"298","volume":"24","author":"B Terhaag","year":"1986","unstructured":"Terhaag B, Donath F, Le Petit G, Feller K. The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison. Int J Clin Pharmacol Ther Toxicol. 1986;24(6):298\u2013302.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"3","key":"5365_CR195","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/03639040601050155","volume":"33","author":"VF Patel","year":"2007","unstructured":"Patel VF, Patel NM. Statistical evaluation of influence of xanthan gum and guar gum blends on dipyridamole release from floating matrix tablets. Drug Dev Ind Pharm. 2007;33(3):327\u201334.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"5365_CR196","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jconrel.2005.12.021","volume":"112","author":"S Siepe","year":"2006","unstructured":"Siepe S, Herrmann W, Borchert HH, Lueckel B, Kramer A, Ries A, et al. Microenvironmental pH and microviscosity inside pH-controlled matrix tablets: an EPR imaging study. J Control Release. 2006;112(1):72\u20138.","journal-title":"J Control Release"},{"issue":"1-2","key":"5365_CR197","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ijpharm.2006.02.021","volume":"316","author":"S Siepe","year":"2006","unstructured":"Siepe S, Lueckel B, Kramer A, Ries A, Gurny R. Strategies for the design of hydrophilic matrix tablets with controlled microenvironmental pH. Int J Pharm. 2006;316(1\u20132):14\u201320.","journal-title":"Int J Pharm"},{"issue":"8","key":"5365_CR198","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1080\/03639040701199209","volume":"33","author":"S Chen","year":"2007","unstructured":"Chen S, Zhu J, Ma F, Fang Q, Li Y. Preparation and characterization of solid dispersions of dipyridamole with a carrier \u201ccopolyvidonum Plasdone S-630.\u201d Drug Dev Ind Pharm. 2007;33(8):888\u201399.","journal-title":"Drug Dev Ind Pharm"},{"issue":"7","key":"5365_CR199","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s12272-011-0709-8","volume":"34","author":"F Guo","year":"2011","unstructured":"Guo F, Zhong H, He J, Xie B, Liu F, Xu H, et al. Self-microemulsifying drug delivery system for improved oral bioavailability of dipyridamole: preparation and evaluation. Arch Pharm Res. 2011;34(7):1113\u201323.","journal-title":"Arch Pharm Res"},{"issue":"2","key":"5365_CR200","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF02555396","volume":"29","author":"I Bayer","year":"1986","unstructured":"Bayer I, Kyzer S, Creter D, Lewinski UH. Rectal bleeding induced by dipyridamole. Dis Colon Rectum. 1986;29(2):123\u20135.","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"5365_CR201","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1021\/acsami.3c13855","volume":"16","author":"F Meng","year":"2024","unstructured":"Meng F, Zhai X, Ma J, Li A, Wang X, Bai J. Enzyme-induced shape-shifting peptide nanocarrier coloaded with paclitaxel and dipyridamole inhibits platelet function and tumor metastasis. ACS Appl Mater Interfaces. 2024;16(1):166\u201377.","journal-title":"ACS Appl Mater Interfaces"},{"key":"5365_CR202","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jconrel.2024.08.043","volume":"375","author":"B Xiao","year":"2024","unstructured":"Xiao B, Shi X, Xu X, Liu J, Pan Y, Xu H, et al. In situ formed reactive oxygen species-responsive dipyridamole prodrug hydrogel: Spatiotemporal drug delivery for chemoimmunotherapy. J Control Release. 2024;375:454\u201366.","journal-title":"J Control Release"},{"issue":"3","key":"5365_CR203","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2165\/00003495-199958030-00007","volume":"58","author":"PS Hervey","year":"1999","unstructured":"Hervey PS, Goa KL. Extended-release dipyridamole\/aspirin. Drugs. 1999;58(3):469\u201375 (discussion 76-7).","journal-title":"Drugs"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05365-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05365-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05365-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:02:15Z","timestamp":1787889735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05365-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":203,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5365"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05365-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1265"}}